Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,210,000 shares, an increase of 107.4% from the December 31st total of 583,500 shares. Based on an average trading volume of 203,100 shares, the days-to-cover ratio is presently 6.0 days. Approximately 9.2% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

SRTS has been the subject of a number of research analyst reports. Maxim Group lifted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. HC Wainwright raised their target price on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, November 18th.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.22 during mid-day trading on Wednesday, reaching $6.70. The stock had a trading volume of 231,987 shares, compared to its average volume of 207,760. The business’s 50 day moving average is $7.60 and its 200 day moving average is $6.82. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The stock has a market cap of $109.81 million, a P/E ratio of 11.75 and a beta of 1.21.

Hedge Funds Weigh In On Sensus Healthcare

Several large investors have recently made changes to their positions in the business. Truvestments Capital LLC bought a new position in Sensus Healthcare during the third quarter valued at about $32,000. XTX Topco Ltd acquired a new stake in Sensus Healthcare in the 2nd quarter valued at about $95,000. Cubist Systematic Strategies LLC bought a new position in Sensus Healthcare in the 2nd quarter worth approximately $156,000. Ritholtz Wealth Management increased its position in Sensus Healthcare by 65.3% in the fourth quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock worth $355,000 after purchasing an additional 20,256 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.